Contact this trialFirst, we need to learn more about you.
Substrate Reduction Therapy
Venglustat for Fabry Disease
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is an 18-month study to evaluate the effect of a new therapy on a heart issue in adults with Fabry Disease. Participants visit every 3-6 months and may continue in the study for up to 18 more months.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service